For intraperitoneal administration (i.p.), 7,8-dihydroxyflavone (7,8-DHF; Catalog number: D5446, Sigma-Aldrich, USA, 5 mg/kg) was prepared in vehicle of 20% β-cyclodextrin in normal saline, and ANA-12 (Catalog number: HY-12497, MedChem Express, USA, 0.5 mg/kg) was prepared in vehicle of 20% β-cyclodextrin in normal saline. The doses of 7,8-DHF (5 mg/kg), and ANA-12 (0.5 mg/kg) were selected as reported previously [31 (link), 46 (link), 47 (link)].
For stereotaxic drug microinjection, Recombinant Human BDNF (rhBDNF; Catalog number: AF-450-02, Peprotech, USA, 0.5 μg/μl, 0.5 μl/site) was prepared in vehicle of 0.1% BSA, 7,8-DHF (1 μg/μl, 0.5 μl/site), and ANA-12 (1 μg/μl, 0.5 μl/site) was prepared in vehicle of 20% β-cyclodextrin in normal saline. The dose of 7,8-DHF was chosen based on our pilot study. The doses of BDNF [48 (link)], and ANA-12 [49 (link)] were selected as reported previously.
For stereotaxic drug microinjection, Recombinant Human BDNF (rhBDNF; Catalog number: AF-450-02, Peprotech, USA, 0.5 μg/μl, 0.5 μl/site) was prepared in vehicle of 0.1% BSA, 7,8-DHF (1 μg/μl, 0.5 μl/site), and ANA-12 (1 μg/μl, 0.5 μl/site) was prepared in vehicle of 20% β-cyclodextrin in normal saline. The dose of 7,8-DHF was chosen based on our pilot study. The doses of BDNF [48 (link)], and ANA-12 [49 (link)] were selected as reported previously.
Free full text: Click here
